Octant

Octant operates at the intersection of biology and chemistry, aiming to navigate the complexities of these fields to pioneer new small molecule drugs. The company’s mission is to map a new universe of medicine through innovative approaches rooted in biology. Octant employs a technology platform that supports the development of next-generation therapeutics, utilizing high-throughput synthetic biology to unravel and model the cellular mechanisms underlying diseases. Additionally, the company leverages high-throughput chemistry techniques to engineer small molecules capable of modulating biological mechanisms. A key feature of Octant’s approach is the use of barcoded multiplexing, which allows for massively parallel, high-throughput drug discovery processes. The company also integrates big data and AI/ML pipelines to enhance the speed and efficiency of its drug development programs. Recently, on December 12, 2023, Octant announced the appointment of Chris Sinz, Matthew Albert, Rebecca Velez Frey, and Wen-Chen Yeh to key leadership positions. In recognition of its innovative technologies, Octant received the ‘Technology and Tools’ Award at the Mutational Scanning Symposium in 2022. Furthermore, the company secured $80 million in Series B funding and formed a strategic partnership with Bristol Myers Squibb on April 21, 2022.